Nixon Peabody Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nixon Peabody Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699K	Hold	2,322	–	–	0.05%	110
2026 Q1	$768K	Sell	2,322 -15	-0.6%	-$5.1K	0.06%	94
2025 Q4	$929K	Sell	2,337 -10	-0.4%	-$4.43K	0.07%	90
2025 Q3	$1.07M	Buy	2,347 +10	+0.4%	+$4.07K	0.08%	88
2025 Q2	$762K	Buy	2,337 +60	+3%	+$16.6K	0.06%	96
2025 Q1	$615K	Sell	2,277 -16	-0.7%	-$4.11K	0.05%	102
2024 Q4	$540K	Buy	2,293 +43	+2%	+$11.3K	0.04%	99
2024 Q3	$619K	Sell	2,250 -1,050	-32%	-$273K	0.05%	91
2024 Q2	$802K	Hold	3,300	–	–	0.07%	75
2024 Q1	$493K	Hold	3,300	–	–	0.05%	90
2023 Q4	$632K	Buy	3,300 +1,800	+120%	+$307K	0.07%	77
2023 Q3	$266K	Hold	1,500	–	–	0.22%	67
2023 Q2	$285K	Hold	1,500	–	–	0.23%	66
2023 Q1	$300K	Hold	1,500	–	–	0.21%	58
2022 Q4	$356K	Hold	1,500	–	–	0.29%	60
2022 Q3	$300K	Hold	1,500	–	–	0.25%	61
2022 Q2	$219K	Hold	1,500	–	–	0.1%	66
2022 Q1	$245K	Hold	1,500	–	–	0.08%	74
2021 Q4	$254K	Hold	1,500	–	–	0.08%	80
2021 Q3	$283K	Sell	1,500 -500	-25%	-$93.8K	0.1%	66
2021 Q2	$339K	Hold	2,000	–	–	0.13%	59
2021 Q1	$282K	Hold	2,000	–	–	0.11%	63
2020 Q4	$260K	Hold	2,000	–	–	0.11%	65
2020 Q3	$291K	Hold	2,000	–	–	0.13%	68
2020 Q2	$296K	Hold	2,000	–	–	0.15%	67
2020 Q1	$218K	Hold	2,000	–	–	0.13%	67
2019 Q4	$230K	Buy	+2,000	New	+$199K	0.11%	74
2018 Q2	–	Sell	-2,000	Closed	-$238K	–	75
2018 Q1	$238K	Hold	2,000	–	–	0.21%	62
2017 Q4	$254K	Hold	2,000	–	–	0.22%	62
2017 Q3	$235K	Buy	+2,000	New	+$171K	0.21%	64

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

Nixon Peabody Trust's ALNY Position: Q2 2026 in Review

Nixon Peabody Trust held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 2,322 shares worth $699K. The position accounts for 0.05% of the portfolio, ranked #110.

Nixon Peabody Trust first reported a position in ALNY in Q3 2017 and has held it in 30 quarters since. The position peaked at $1.07M in Q3 2025. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Nixon Peabody Trust held 2,322 shares of Alnylam Pharmaceuticals worth $699K as of Q2 2026.
Nixon Peabody Trust left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.05% of Nixon Peabody Trust's portfolio in Q2 2026, its #110 holding.
Nixon Peabody Trust first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 30 quarters since.
Nixon Peabody Trust's Alnylam Pharmaceuticals position peaked at $1.07M in Q3 2025.
194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.